NO20056010L - Biaryloksymetylaren-karboksylsyrer - Google Patents

Biaryloksymetylaren-karboksylsyrer

Info

Publication number
NO20056010L
NO20056010L NO20056010A NO20056010A NO20056010L NO 20056010 L NO20056010 L NO 20056010L NO 20056010 A NO20056010 A NO 20056010A NO 20056010 A NO20056010 A NO 20056010A NO 20056010 L NO20056010 L NO 20056010L
Authority
NO
Norway
Prior art keywords
biaryloksymetylaren
acids
compounds
diabetes
treating
Prior art date
Application number
NO20056010A
Other languages
English (en)
Inventor
Jefferson Wright Tilley
Chang An Chu
Paul Gillespie
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33556418&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20056010(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20056010L publication Critical patent/NO20056010L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40—Thiophene-2-carboxylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår forbindelser med formel (I) hvor R1, R2, R3, R4, m, n, p og s er som definert i beskrivelsen og kravene og farmasøytisk akseptable salter derav og farmasøytiske preparater derav. Forbindelsene er anvendelige for behandling og/eller forebygging av sykdommer som er forbundet med aktivering av glykogen-syntase-enzym, så som diabetes.
NO20056010A 2003-06-24 2005-12-16 Biaryloksymetylaren-karboksylsyrer NO20056010L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US48090003P 2003-06-24 2003-06-24
US48214703P 2003-06-24 2003-06-24
US56935604P 2004-05-07 2004-05-07
PCT/EP2004/006611 WO2005000781A1 (en) 2003-06-24 2004-06-18 Biaryloxymethylarene-carboxylic acids

Publications (1)

Publication Number Publication Date
NO20056010L true NO20056010L (no) 2006-01-20

Family

ID=33556418

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20056010A NO20056010L (no) 2003-06-24 2005-12-16 Biaryloksymetylaren-karboksylsyrer

Country Status (22)

Country Link
US (3) US7355049B2 (no)
EP (1) EP1663936B1 (no)
JP (1) JP4471974B2 (no)
KR (1) KR100809205B1 (no)
AR (1) AR044856A1 (no)
AT (1) ATE383329T1 (no)
AU (1) AU2004251846B2 (no)
BR (1) BRPI0411906A (no)
CA (1) CA2529875A1 (no)
CO (1) CO5640098A2 (no)
DE (1) DE602004011239T2 (no)
DK (1) DK1663936T3 (no)
ES (1) ES2298761T3 (no)
IL (1) IL172617A0 (no)
MX (1) MXPA05014082A (no)
MY (1) MY138708A (no)
NO (1) NO20056010L (no)
NZ (1) NZ544150A (no)
PL (1) PL1663936T3 (no)
PT (1) PT1663936E (no)
TW (2) TW200817350A (no)
WO (1) WO2005000781A1 (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2441474B1 (en) * 2003-10-17 2015-08-05 Joslin Diabetes Center, Inc. Methods and compositions for modulating adipocyte function
US7524870B2 (en) * 2004-12-03 2009-04-28 Hoffmann-La Roche Inc. Biaryloxymethylarenecarboxylic acids as glycogen synthase activators
GB0503053D0 (en) * 2005-02-14 2005-03-23 Smithkline Beecham Corp Chemical compounds
US20100150885A1 (en) * 2005-06-01 2010-06-17 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
AU2009244308A1 (en) * 2008-05-06 2009-11-12 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
EP2348857B1 (en) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP5557845B2 (ja) 2008-10-31 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
US20110112158A1 (en) 2009-11-11 2011-05-12 David Robert Bolin Benzisoxazole analogs as glycogen synthase activators
US7947728B1 (en) 2009-11-11 2011-05-24 Hoffmann-La Roche Inc. Indole and indazole analogs as glycogen synthase activators
US20110112147A1 (en) 2009-11-11 2011-05-12 David Robert Bolin Indazolone analogs as glycogen synthase activators
US8039495B2 (en) 2009-11-16 2011-10-18 Hoffman-La Roche Inc. Biphenyl carboxylic acids and bioisosteres as glycogen synthase activators
US20110118314A1 (en) 2009-11-16 2011-05-19 Weiya Yun Piperidine analogs as glycogen synthase activators
US7939569B1 (en) 2009-12-01 2011-05-10 Hoffmann-La Roche Inc. Aniline analogs as glycogen synthase activators
US20110136792A1 (en) 2009-12-04 2011-06-09 David Robert Bolin Novel carboxylic acid analogs as glycogen synthase activators
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
MX2013006768A (es) 2010-12-23 2013-07-22 Pfizer Moduladores de receptor de glucagon.
ES2597972T3 (es) 2011-02-08 2017-01-24 Pfizer Inc Modulador del receptor de glucagón
MX348131B (es) 2011-02-25 2017-05-26 Merck Sharp & Dohme Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos.
RU2013157388A (ru) 2011-07-22 2015-08-27 Пфайзер Инк. Хинолинильные модуляторы глюкагонового рецептора
WO2013065835A1 (ja) 2011-11-04 2013-05-10 味の素株式会社 糖尿病治療用医薬組成物
US9382188B2 (en) 2012-02-13 2016-07-05 Takeda Pharmaceutical Company Limited Aromatic ring compound
WO2014022528A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2014130608A1 (en) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
JP2016130214A (ja) 2013-05-01 2016-07-21 味の素株式会社 糖尿病治療用医薬組成物
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2016002853A1 (ja) * 2014-07-01 2016-01-07 味の素株式会社 糖尿病治療用医薬組成物
JP6699011B2 (ja) * 2014-07-04 2020-05-27 国立大学法人 東京大学 脂肪酸サロゲートを含むリゾホスファチジルセリン誘導体
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298B1 (en) 2016-12-20 2026-03-11 Merck Sharp & Dohme LLC Antidiabetic spirochroman compounds
US11490813B2 (en) * 2019-06-25 2022-11-08 St. Jude Medical Luxembourg Holdings Ii S.A.R.L. (“Sjm Lux 11”) Method and system for managing energy transfer between a passive implanted medical device and external device
WO2022198196A1 (en) 2021-03-15 2022-09-22 Maze Therapeutics, Inc. Inhibitors of glycogen synthase 1 (gys1) and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2842243A1 (de) 1978-09-28 1980-04-10 Hoechst Ag Furan- und thiophen-carbonsaeure-derivate und verfahren zu ihrer herstellung
DE4142514A1 (de) 1991-12-21 1993-06-24 Basf Ag Verfahren zur bekaempfung von pilzen
WO1993024442A1 (fr) 1992-05-29 1993-12-09 Yamanouchi Pharmaceutical Co., Ltd. Medicament renfermant un derive d'acide benzoique, et nouveau derive d'acide benzoique
JP2000509373A (ja) 1996-04-19 2000-07-25 ノボ ノルディスク アクティーゼルスカブ ホスホチロシン認識ユニットを有する分子のモジュレーター
US6043247A (en) 1996-04-19 2000-03-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
JP2000511883A (ja) 1996-04-19 2000-09-12 ノボ ノルディスク アクティーゼルスカブ ホスホチロシン認識ユニットを有する分子のモジュレーター
JP4121215B2 (ja) * 1999-05-17 2008-07-23 財団法人微生物化学研究会 スルフォスチン類縁体、並びにスルフォスチン及びその類縁体の製造方法
WO2004012656A2 (en) 2002-08-02 2004-02-12 Applied Research Systems Ars Holding N.V. Thiophene and furan derivatives as prostaglandin agonists and use thereof
JP2006511587A (ja) 2002-12-20 2006-04-06 ミジェニックス コーポレイション アデニンヌクレオチドトランスロカーゼ（ａｎｔ）リガンドならびにそれに関連する組成物および方法
DK1603893T3 (da) 2003-01-29 2008-09-08 Asterand Uk Ltd EP4 -Receptorantagonister

Also Published As

Publication number Publication date
US20080108662A1 (en) 2008-05-08
HK1093724A1 (zh) 2007-03-09
ES2298761T3 (es) 2008-05-16
JP2007506666A (ja) 2007-03-22
EP1663936A1 (en) 2006-06-07
PT1663936E (pt) 2008-02-04
US20080255198A1 (en) 2008-10-16
US7842825B2 (en) 2010-11-30
CO5640098A2 (es) 2006-05-31
CA2529875A1 (en) 2005-01-06
JP4471974B2 (ja) 2010-06-02
NZ544150A (en) 2008-12-24
KR100809205B1 (ko) 2008-02-29
AU2004251846B2 (en) 2010-02-04
MY138708A (en) 2009-07-31
TW200517389A (en) 2005-06-01
KR20060059910A (ko) 2006-06-02
TW200817350A (en) 2008-04-16
AR044856A1 (es) 2005-10-05
BRPI0411906A (pt) 2006-08-08
DE602004011239T2 (de) 2009-01-08
AU2004251846A1 (en) 2005-01-06
MXPA05014082A (es) 2006-03-02
TWI302532B (en) 2008-11-01
US7355049B2 (en) 2008-04-08
US20040266856A1 (en) 2004-12-30
IL172617A0 (en) 2006-04-10
US7700632B2 (en) 2010-04-20
WO2005000781A1 (en) 2005-01-06
DE602004011239D1 (de) 2008-02-21
ATE383329T1 (de) 2008-01-15
EP1663936B1 (en) 2008-01-09
PL1663936T3 (pl) 2008-06-30
DK1663936T3 (da) 2008-03-31

Similar Documents

Publication Publication Date Title
NO20072608L (no) Biaryloksymetylarenkarboksylsyrer
MXPA05014082A (es) Acidos biariloximetilarenocarboxilicos.
NO20085066L (no) 4,5-difenyl-pyrimidinyl-aminosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
NO20055887L (no) Pyrido'2, 1-A-isokinoliderivater som DPP-IV-inhibitorer
NO20085064L (no) 4,5-difenyl-pyrimidinyl-oksy eller -merkaptosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
NO20055680L (no) Heksahydropyridoisokinoliner som DPP-IV-inhibitorer
NO20053748L (no) Pyrrolopyridazinderivater.
JO2282B1 (en) Oxazole derivatives
NO20072689L (no) Tetrasykliske indolderivater som antivirale midler
NO20072389L (no) Substituerte benzokinolizinderivater
TW200615266A (en) Organic compounds
NO20085068L (no) Fenylamino-benzoksazolsubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
NO20085169L (no) Krystallinske solvater og komplekser av (1S)-1,5-anhydro-L-C- (3-((fenyl)metyl)fenyl)-D-glucitol derivater med aminosyrer som SGLT2-inhibitorer for behandling av diabetes
WO2007061360A3 (en) Novel 3-bicyclocarbonylaminopyridine-2-carboxamides or 3-bicyclocarbonylaminopyrazine-2-carboxamides
WO2006005609A3 (de) Substituierte oxindol-derivate und diese enthaltende arzneimittel
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
NO20082136L (no) 1,5-substituerte indol-2-yl-amidderivater
WO2004033455A3 (en) Hemisuccinate salts of heterocyclic dpp-iv inhibitors
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
MX2007010532A (es) Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii.
NO20082096L (no) Azaindol-2-karboksamidderivativer
WO2006100081A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
NO20080394L (no) N-(arylalkyl)-1H-pyrrolopyridin-2-karboksamidderivater, fremstilling og anvendelse derav
WO2006100082A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
NO20090067L (no) Farmasoytiske kombinasjoner for behandling av respiratoriske sykdommer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application